Keya Medical completed a $46 million D financing in late December to support its automated scanning products based on deep learning algorithms. It was the company's fourth funding in 2020 that included a $22 million Series B+ and a $14 million Series B. The company is headquartered in Seattle , where it is known a CuraCloud, with operations in Beijing and Shenzhen. All of its investors are China-based firms. Keya markets products that analyze cardiovascular and neurological conditions. More details.... Share this with colleagues: // //